vs
固瑞克（GGG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是固瑞克的1.3倍（$772.1M vs $593.2M），固瑞克净利率更高（22.3% vs 12.7%，领先9.6%），固瑞克同比增速更快（8.1% vs 5.9%），固瑞克自由现金流更多（$184.3M vs $161.8M），过去两年固瑞克的营收复合增速更高（9.8% vs 9.0%）
固瑞克（Graco Inc.）是总部位于美国明尼苏达州明尼阿波利斯的工业企业，专注于流体处理系统及相关产品的研发与制造，旗下产品销往全球各地，广泛应用于多个工业领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GGG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$593.2M
营收增速更快
GGG
高出2.3%
5.9%
净利率更高
GGG
高出9.6%
12.7%
自由现金流更多
GGG
多$22.5M
$161.8M
两年增速更快
GGG
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $593.2M | $772.1M |
| 净利润 | $132.5M | $98.4M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 26.7% | 14.5% |
| 净利率 | 22.3% | 12.7% |
| 营收同比 | 8.1% | 5.9% |
| 净利润同比 | 21.9% | 3.9% |
| 每股收益（稀释后） | $0.78 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GGGRVTY
| Q4 25 | $593.2M | $772.1M | ||
| Q3 25 | $543.4M | $698.9M | ||
| Q2 25 | $571.8M | $720.3M | ||
| Q1 25 | $528.3M | $664.8M | ||
| Q4 24 | $548.7M | $729.4M | ||
| Q3 24 | $519.2M | $684.0M | ||
| Q2 24 | $553.2M | $691.7M | ||
| Q1 24 | $492.2M | $649.9M |
净利润GGGRVTY
| Q4 25 | $132.5M | $98.4M | ||
| Q3 25 | $137.6M | $46.7M | ||
| Q2 25 | $127.6M | $53.9M | ||
| Q1 25 | $124.1M | $42.2M | ||
| Q4 24 | $108.7M | $94.6M | ||
| Q3 24 | $122.2M | $94.4M | ||
| Q2 24 | $133.0M | $55.4M | ||
| Q1 24 | $122.2M | $26.0M |
毛利率GGGRVTY
| Q4 25 | 51.7% | — | ||
| Q3 25 | 53.2% | 53.6% | ||
| Q2 25 | 52.4% | 54.5% | ||
| Q1 25 | 52.6% | 56.5% | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 53.2% | 56.3% | ||
| Q2 24 | 54.4% | 55.7% | ||
| Q1 24 | 54.1% | 54.6% |
营业利润率GGGRVTY
| Q4 25 | 26.7% | 14.5% | ||
| Q3 25 | 30.3% | 11.7% | ||
| Q2 25 | 27.5% | 12.6% | ||
| Q1 25 | 27.3% | 10.9% | ||
| Q4 24 | 23.7% | 16.3% | ||
| Q3 24 | 28.1% | 14.3% | ||
| Q2 24 | 29.2% | 12.4% | ||
| Q1 24 | 27.0% | 6.8% |
净利率GGGRVTY
| Q4 25 | 22.3% | 12.7% | ||
| Q3 25 | 25.3% | 6.7% | ||
| Q2 25 | 22.3% | 7.5% | ||
| Q1 25 | 23.5% | 6.4% | ||
| Q4 24 | 19.8% | 13.0% | ||
| Q3 24 | 23.5% | 13.8% | ||
| Q2 24 | 24.0% | 8.0% | ||
| Q1 24 | 24.8% | 4.0% |
每股收益（稀释后）GGGRVTY
| Q4 25 | $0.78 | $0.86 | ||
| Q3 25 | $0.82 | $0.40 | ||
| Q2 25 | $0.76 | $0.46 | ||
| Q1 25 | $0.72 | $0.35 | ||
| Q4 24 | $0.63 | $0.77 | ||
| Q3 24 | $0.71 | $0.77 | ||
| Q2 24 | $0.77 | $0.45 | ||
| Q1 24 | $0.71 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $624.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $3.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GGGRVTY
| Q4 25 | $624.1M | $919.9M | ||
| Q3 25 | $618.7M | $931.4M | ||
| Q2 25 | $534.9M | $991.8M | ||
| Q1 25 | $536.1M | $1.1B | ||
| Q4 24 | $675.3M | $1.2B | ||
| Q3 24 | $764.5M | $1.2B | ||
| Q2 24 | $666.0M | $2.0B | ||
| Q1 24 | $622.7M | $1.7B |
股东权益GGGRVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.5B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.6B | $7.7B | ||
| Q3 24 | $2.5B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
总资产GGGRVTY
| Q4 25 | $3.3B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.0B | $12.4B | ||
| Q1 25 | $3.0B | $12.4B | ||
| Q4 24 | $3.1B | $12.4B | ||
| Q3 24 | $3.0B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $2.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $196.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $184.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 31.1% | 21.0% |
| 资本支出强度资本支出/营收 | 2.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.48× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $637.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GGGRVTY
| Q4 25 | $196.3M | $182.0M | ||
| Q3 25 | $179.2M | $138.5M | ||
| Q2 25 | $182.7M | $134.3M | ||
| Q1 25 | $125.4M | $128.2M | ||
| Q4 24 | $185.2M | $174.2M | ||
| Q3 24 | $178.6M | $147.9M | ||
| Q2 24 | $139.0M | $158.6M | ||
| Q1 24 | $118.9M | $147.6M |
自由现金流GGGRVTY
| Q4 25 | $184.3M | $161.8M | ||
| Q3 25 | $175.7M | $120.0M | ||
| Q2 25 | $163.1M | $115.5M | ||
| Q1 25 | $114.8M | $112.2M | ||
| Q4 24 | $171.3M | $149.8M | ||
| Q3 24 | $159.2M | $125.6M | ||
| Q2 24 | $102.7M | $136.6M | ||
| Q1 24 | $81.7M | $129.7M |
自由现金流率GGGRVTY
| Q4 25 | 31.1% | 21.0% | ||
| Q3 25 | 32.3% | 17.2% | ||
| Q2 25 | 28.5% | 16.0% | ||
| Q1 25 | 21.7% | 16.9% | ||
| Q4 24 | 31.2% | 20.5% | ||
| Q3 24 | 30.7% | 18.4% | ||
| Q2 24 | 18.6% | 19.7% | ||
| Q1 24 | 16.6% | 20.0% |
资本支出强度GGGRVTY
| Q4 25 | 2.0% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 3.4% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 2.5% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 6.6% | 3.2% | ||
| Q1 24 | 7.6% | 2.7% |
现金转化率GGGRVTY
| Q4 25 | 1.48× | 1.85× | ||
| Q3 25 | 1.30× | 2.97× | ||
| Q2 25 | 1.43× | 2.49× | ||
| Q1 25 | 1.01× | 3.03× | ||
| Q4 24 | 1.70× | 1.84× | ||
| Q3 24 | 1.46× | 1.57× | ||
| Q2 24 | 1.05× | 2.87× | ||
| Q1 24 | 0.97× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GGG
| Industrial | $284.3M | 48% |
| Contractor | $265.5M | 45% |
| Other | $43.4M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
